Suppr超能文献

相对于其表位精细特异性而言,针对HIV-1 gp120 V3环区的抗体的中和活性。

Neutralizing activity of antibodies to the V3 loop region of HIV-1 gp120 relative to their epitope fine specificity.

作者信息

Pantophlet Ralph, Wrin Terri, Cavacini Lisa A, Robinson James E, Burton Dennis R

机构信息

The Scripps Research Institute, Department of Immunology and Microbial Science, IMM2, 10550 North Torrey Pines Road La Jolla, CA 92037, USA.

出版信息

Virology. 2008 Nov 25;381(2):251-60. doi: 10.1016/j.virol.2008.08.032. Epub 2008 Sep 26.

Abstract

The V3 loop of HIV-1 gp120 is considered occluded on many primary viruses. However, virus sensitivity to neutralization by different V3 mAbs often varies, indicating that access to V3 is not restricted equally for all antibodies. Here, we have sought to gain a better understanding of these restrictions by determining the neutralizing activities of 7 V3 mAbs (19b, 39F, CO11, F2A3, F530, LA21, and LE311) against 15 subtype B primary isolates and relating these activities to the fine specificity of the mAbs. Not surprisingly, we found that most mAbs neutralized the same 2-3 viruses, with only mAb F530 able to neutralize 2 additional viruses not neutralized by the other mAbs. Epitope mapping revealed that positively-charged residues in or near the V3 stem are important for the binding of all the mAbs and that most mAbs seem to require the Pro residue that forms the GPGR beta hairpin turn in the V3 tip for binding. Based on the mapping, we determined that V3 sequence variation accounted for neutralization resistance of approximately half the viruses tested. Comparison of these results to those of select V3 mAbs with overall better neutralizing activities in the light of structural information illustrates how an antibody's mode of interaction with V3, driven by contact residue requirements, may restrict the antibody from accessing its epitope on different viruses. Based on the data we propose an angle of interaction with V3 that is less stringent on access for antibodies with cross-neutralizing activity compared to antibodies that neutralize relatively fewer viruses.

摘要

HIV-1 gp120的V3环在许多原始病毒上被认为是封闭的。然而,病毒对不同V3单克隆抗体中和作用的敏感性常常有所不同,这表明并非所有抗体接近V3的途径都受到同等限制。在此,我们试图通过测定7种V3单克隆抗体(19b、39F、CO11、F2A3、F530、LA21和LE311)对15株B亚型原始分离株的中和活性,并将这些活性与单克隆抗体的精细特异性相关联,从而更好地理解这些限制。不出所料,我们发现大多数单克隆抗体中和相同的2 - 3种病毒,只有单克隆抗体F530能够中和另外2种未被其他单克隆抗体中和的病毒。表位作图显示,V3茎干中或附近的带正电荷残基对所有单克隆抗体的结合都很重要,并且大多数单克隆抗体似乎需要V3尖端形成GPGRβ发夹转折的脯氨酸残基才能结合。基于该作图,我们确定V3序列变异约占所测试病毒中和抗性的一半。根据结构信息,将这些结果与具有总体更好中和活性的特定V3单克隆抗体的结果进行比较,说明了由接触残基要求驱动的抗体与V3的相互作用模式如何可能限制抗体在不同病毒上接近其表位。基于这些数据,我们提出了一种与V3的相互作用角度,与中和相对较少病毒的抗体相比,对具有交叉中和活性的抗体接近V3的要求不太严格。

相似文献

1
Neutralizing activity of antibodies to the V3 loop region of HIV-1 gp120 relative to their epitope fine specificity.
Virology. 2008 Nov 25;381(2):251-60. doi: 10.1016/j.virol.2008.08.032. Epub 2008 Sep 26.
2
The cross-clade neutralizing activity of a human monoclonal antibody is determined by the GPGR V3 motif of HIV type 1.
AIDS Res Hum Retroviruses. 2004 Nov;20(11):1254-8. doi: 10.1089/aid.2004.20.1254.
6
Worldwide distribution of HIV type 1 epitopes recognized by human anti-V3 monoclonal antibodies.
AIDS Res Hum Retroviruses. 2009 Apr;25(4):441-50. doi: 10.1089/aid.2008.0188.
8
Quantitative assessment of masking of neutralization epitopes in HIV-1.
Vaccine. 2011 Sep 9;29(39):6736-41. doi: 10.1016/j.vaccine.2010.12.052. Epub 2011 Jan 7.
9
Distinct mechanisms regulate exposure of neutralizing epitopes in the V2 and V3 loops of HIV-1 envelope.
J Virol. 2014 Nov;88(21):12853-65. doi: 10.1128/JVI.02125-14. Epub 2014 Aug 27.

引用本文的文献

1
Membrane HIV-1 envelope glycoproteins stabilized more strongly in a pretriggered conformation than natural virus Envs.
iScience. 2024 May 28;27(7):110141. doi: 10.1016/j.isci.2024.110141. eCollection 2024 Jul 19.
2
Anti-HIV-1 Nanobody-IgG1 Constructs With Improved Neutralization Potency and the Ability to Mediate Fc Effector Functions.
Front Immunol. 2022 May 16;13:893648. doi: 10.3389/fimmu.2022.893648. eCollection 2022.
4
Display of the HIV envelope protein at the yeast cell surface for immunogen development.
PLoS One. 2018 Oct 18;13(10):e0205756. doi: 10.1371/journal.pone.0205756. eCollection 2018.
5
Rational Design of DNA-Expressed Stabilized Native-Like HIV-1 Envelope Trimers.
Cell Rep. 2018 Sep 18;24(12):3324-3338.e5. doi: 10.1016/j.celrep.2018.08.051.
8
Ibalizumab Targeting CD4 Receptors, An Emerging Molecule in HIV Therapy.
Front Microbiol. 2017 Nov 27;8:2323. doi: 10.3389/fmicb.2017.02323. eCollection 2017.

本文引用的文献

1
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection.
Proc Natl Acad Sci U S A. 2008 May 27;105(21):7552-7. doi: 10.1073/pnas.0802203105. Epub 2008 May 19.
2
The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus.
Nat Rev Microbiol. 2008 Feb;6(2):143-55. doi: 10.1038/nrmicro1819.
3
Structure of antibody F425-B4e8 in complex with a V3 peptide reveals a new binding mode for HIV-1 neutralization.
J Mol Biol. 2008 Jan 25;375(4):969-78. doi: 10.1016/j.jmb.2007.11.013. Epub 2007 Nov 13.
4
Passive immunization as tool to identify protective HIV-1 Env epitopes.
Curr HIV Res. 2007 Nov;5(6):642-55. doi: 10.2174/157016207782418506.
5
Prospects of HIV Env modification as an approach to HIV vaccine design.
Curr HIV Res. 2007 Nov;5(6):507-13. doi: 10.2174/157016207782418542.
7
Clustal W and Clustal X version 2.0.
Bioinformatics. 2007 Nov 1;23(21):2947-8. doi: 10.1093/bioinformatics/btm404. Epub 2007 Sep 10.
8
Development of an HIV-1 reference panel of subtype B envelope clones isolated from the plasma of recently infected individuals.
J Acquir Immune Defic Syndr. 2007 Sep 1;46(1):1-11. doi: 10.1097/QAI.0b013e318074eb5a.
10
Structural definition of a conserved neutralization epitope on HIV-1 gp120.
Nature. 2007 Feb 15;445(7129):732-7. doi: 10.1038/nature05580.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验